Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma

NCT02955771 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Hilar Cholangiocarcinoma

Interventions

COMBINATION_PRODUCT: PDT-Deuteporfin（6 hour)
COMBINATION_PRODUCT: PDT-Deuteporfin（9 hour)
DEVICE: stenting

Sponsor

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.